SA515360469B1 - مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها - Google Patents
مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامهاInfo
- Publication number
- SA515360469B1 SA515360469B1 SA515360469A SA515360469A SA515360469B1 SA 515360469 B1 SA515360469 B1 SA 515360469B1 SA 515360469 A SA515360469 A SA 515360469A SA 515360469 A SA515360469 A SA 515360469A SA 515360469 B1 SA515360469 B1 SA 515360469B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- methods
- heterocyclic compounds
- inhibiting glutaminase
- glutaminase
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Abstract
يتعلق الاختراع الحالي مركب وفقا للصيغة (I) أو تركيبة مقبولة صيدلانيا منه: الصيغة (I)، واستخدامها في تحضير تركيبات صيدلانية لتثبيط inhibit نشاط إنزيم جلوتاميناز glutaminase لمعالجة أمراض السرطان cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/085023 WO2014079011A1 (en) | 2012-11-22 | 2012-11-22 | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| PCT/CN2013/000294 WO2014079136A1 (en) | 2012-11-22 | 2013-03-15 | Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof |
| PCT/CN2013/001428 WO2014079150A1 (en) | 2012-11-22 | 2013-11-21 | Compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA515360469B1 true SA515360469B1 (ar) | 2017-07-11 |
Family
ID=50775393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA515360469A SA515360469B1 (ar) | 2012-11-22 | 2015-05-22 | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10087172B2 (ar) |
| EP (2) | EP2922850B1 (ar) |
| JP (2) | JP6333277B2 (ar) |
| KR (1) | KR20150085079A (ar) |
| CN (2) | CN108727307A (ar) |
| AR (1) | AR093598A1 (ar) |
| AU (2) | AU2013347771B2 (ar) |
| BR (1) | BR112015011830A2 (ar) |
| CA (1) | CA2893510C (ar) |
| CL (1) | CL2015001392A1 (ar) |
| CR (1) | CR20150316A (ar) |
| CY (1) | CY1120581T1 (ar) |
| DK (1) | DK2922850T3 (ar) |
| EA (2) | EA030646B1 (ar) |
| EC (1) | ECSP15026557A (ar) |
| ES (1) | ES2690390T3 (ar) |
| HK (1) | HK1214593A1 (ar) |
| HR (1) | HRP20181628T1 (ar) |
| HU (1) | HUE040111T2 (ar) |
| IL (1) | IL238958B (ar) |
| LT (1) | LT2922850T (ar) |
| MX (1) | MX367389B (ar) |
| MY (1) | MY177344A (ar) |
| NZ (1) | NZ708382A (ar) |
| PE (1) | PE20151072A1 (ar) |
| PH (2) | PH12015501150A1 (ar) |
| PL (1) | PL2922850T3 (ar) |
| PT (1) | PT2922850T (ar) |
| RS (1) | RS57859B1 (ar) |
| SA (1) | SA515360469B1 (ar) |
| SG (2) | SG11201504049VA (ar) |
| SI (1) | SI2922850T1 (ar) |
| TR (1) | TR201812360T4 (ar) |
| TW (2) | TW201906825A (ar) |
| UA (1) | UA117360C2 (ar) |
| WO (3) | WO2014079011A1 (ar) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| WO2014078645A1 (en) | 2012-11-16 | 2014-05-22 | Calithera Biosciences, Inc. | Heterocyclic glutaminase inhibitors |
| EA029531B1 (ru) | 2012-11-21 | 2018-04-30 | Аджиос Фармасьютикалз, Инк. | Соединения, ингибирующие глутаминазу, и содержащие эти соединения фармацевтические композиции и их применение |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CA2892817A1 (en) * | 2012-12-03 | 2014-06-12 | Calithera Biosciences Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| SG11201601259YA (en) | 2013-08-23 | 2016-03-30 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| KR20160100407A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제의 저해제 |
| MX2016012244A (es) | 2014-03-21 | 2017-05-08 | Agios Pharmaceuticals Inc | Compuestos y sus metodos de uso. |
| JP6574203B2 (ja) * | 2014-04-30 | 2019-09-11 | ファイザー・インク | シクロアルキル結合ジヘテロ環誘導体 |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| AU2015283850B2 (en) * | 2014-07-03 | 2020-06-04 | Board Of Regents, University Of Texas System | GLS1 inhibitors for treating disease |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016014890A1 (en) * | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| SG11201700816YA (en) | 2014-08-07 | 2017-02-27 | Calithera Biosciences Inc | Crystal forms of glutaminase inhibitors |
| US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
| KR20170132333A (ko) | 2015-04-06 | 2017-12-01 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제 억제제에 의한 폐암의 치료 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| ES2794868T3 (es) | 2015-06-30 | 2020-11-19 | Univ Texas | Inhibidores de GLS1 para el tratamiento de enfermedades |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| SG11201802830QA (en) | 2015-10-05 | 2018-05-30 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| TW201731511A (zh) * | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
| CN106890184B (zh) * | 2015-12-18 | 2019-06-25 | 诺言医药科技(上海)有限公司 | 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用 |
| CN108602782B (zh) | 2015-12-22 | 2022-06-17 | 德克萨斯大学系统董事会 | N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 |
| BR112019003533A2 (pt) * | 2016-08-25 | 2019-05-21 | Calithera Biosciences Inc. | terapia de combinação com inibidores de glutaminase |
| JP2019524852A (ja) | 2016-08-25 | 2019-09-05 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を用いる併用療法 |
| US10722487B2 (en) | 2017-10-18 | 2020-07-28 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| EP3876928A4 (en) | 2018-11-08 | 2022-08-10 | Merck Sharp & Dohme Corp. | HISTONE DEACETYLASE INHIBITORS USEFUL IN TREATING OR PREVENTING HIV INFECTION |
| WO2020191356A1 (en) * | 2019-03-21 | 2020-09-24 | Goncalves Marcus | Anti-fructose therapy for colorectal and small intestine cancers |
| CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
| CN112898200A (zh) * | 2021-01-20 | 2021-06-04 | 都创(上海)医药科技股份有限公司 | 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
| US4070400A (en) | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| SU1761672A1 (ru) * | 1990-05-22 | 1992-09-15 | Белгородский технологический институт строительных материалов им.И.А.Гришманова | Способ получени тонкодисперсного мела |
| JPH08508270A (ja) | 1993-03-29 | 1996-09-03 | ビーエーエスエフ アクチエンゲゼルシャフト | マルチ・ドラッグ耐性のモジュレーターとしての１−アミノ−３−フェノキシ−プロパン誘導体 |
| US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
| CA2332325A1 (en) | 1998-06-18 | 1999-12-23 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| US20030054985A1 (en) | 2000-02-22 | 2003-03-20 | Stuart Aaronson | N-cadherin modulated migration, invasion, and metastasis |
| US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| DK1388734T3 (da) | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Metode til opløsningsbaseret diagnose |
| WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
| US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US8716472B2 (en) | 2006-10-16 | 2014-05-06 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
| JP5745272B2 (ja) | 2007-11-19 | 2015-07-08 | ジェネンテック， インコーポレイテッド | 腫瘍進行を阻害するための組成物及び方法 |
| WO2009111067A2 (en) | 2008-03-07 | 2009-09-11 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation |
| WO2010096574A1 (en) | 2009-02-20 | 2010-08-26 | Lisanti Michael P | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
| WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
| JP2012524280A (ja) | 2009-04-17 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー |
| US20130109643A1 (en) * | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| EP3719502A1 (en) | 2010-06-23 | 2020-10-07 | University of Louisville Research Foundation, Inc. | Use of fatty acids in methods for detecting cancer |
| WO2012006506A1 (en) * | 2010-07-09 | 2012-01-12 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| AU2012340866B2 (en) * | 2011-11-21 | 2017-03-16 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| WO2013138790A1 (en) | 2012-03-15 | 2013-09-19 | Research Foundation Of State University Of New York | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
| EA029531B1 (ru) | 2012-11-21 | 2018-04-30 | Аджиос Фармасьютикалз, Инк. | Соединения, ингибирующие глутаминазу, и содержащие эти соединения фармацевтические композиции и их применение |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014138391A1 (en) | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
| KR20160100407A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제의 저해제 |
| MX2016012244A (es) | 2014-03-21 | 2017-05-08 | Agios Pharmaceuticals Inc | Compuestos y sus metodos de uso. |
-
2012
- 2012-11-22 WO PCT/CN2012/085023 patent/WO2014079011A1/en active Application Filing
-
2013
- 2013-03-15 WO PCT/CN2013/000294 patent/WO2014079136A1/en active Application Filing
- 2013-11-21 MX MX2015006493A patent/MX367389B/es active IP Right Grant
- 2013-11-21 DK DK13857585.7T patent/DK2922850T3/en active
- 2013-11-21 JP JP2015543242A patent/JP6333277B2/ja not_active Expired - Fee Related
- 2013-11-21 NZ NZ708382A patent/NZ708382A/en unknown
- 2013-11-21 PT PT13857585T patent/PT2922850T/pt unknown
- 2013-11-21 ES ES13857585.7T patent/ES2690390T3/es active Active
- 2013-11-21 CN CN201810824418.2A patent/CN108727307A/zh active Pending
- 2013-11-21 EP EP13857585.7A patent/EP2922850B1/en active Active
- 2013-11-21 PE PE2015000674A patent/PE20151072A1/es unknown
- 2013-11-21 EP EP18183580.2A patent/EP3456719A1/en not_active Withdrawn
- 2013-11-21 RS RS20181133A patent/RS57859B1/sr unknown
- 2013-11-21 SG SG11201504049VA patent/SG11201504049VA/en unknown
- 2013-11-21 BR BR112015011830A patent/BR112015011830A2/pt not_active Application Discontinuation
- 2013-11-21 MY MYPI2015001355A patent/MY177344A/en unknown
- 2013-11-21 HU HUE13857585A patent/HUE040111T2/hu unknown
- 2013-11-21 EA EA201590987A patent/EA030646B1/ru not_active IP Right Cessation
- 2013-11-21 PL PL13857585T patent/PL2922850T3/pl unknown
- 2013-11-21 CA CA2893510A patent/CA2893510C/en active Active
- 2013-11-21 WO PCT/CN2013/001428 patent/WO2014079150A1/en active Application Filing
- 2013-11-21 LT LTEP13857585.7T patent/LT2922850T/lt unknown
- 2013-11-21 TR TR2018/12360T patent/TR201812360T4/tr unknown
- 2013-11-21 SG SG10201609940RA patent/SG10201609940RA/en unknown
- 2013-11-21 EA EA201890754A patent/EA201890754A1/ru unknown
- 2013-11-21 SI SI201331140T patent/SI2922850T1/sl unknown
- 2013-11-21 AU AU2013347771A patent/AU2013347771B2/en not_active Ceased
- 2013-11-21 CN CN201380070365.5A patent/CN104936954B/zh not_active Expired - Fee Related
- 2013-11-21 UA UAA201506066A patent/UA117360C2/uk unknown
- 2013-11-21 KR KR1020157016414A patent/KR20150085079A/ko not_active Application Discontinuation
- 2013-11-21 US US14/646,634 patent/US10087172B2/en active Active
- 2013-11-22 TW TW107111990A patent/TW201906825A/zh unknown
- 2013-11-22 TW TW102142566A patent/TWI629268B/zh not_active IP Right Cessation
- 2013-11-22 AR ARP130104322A patent/AR093598A1/es unknown
-
2015
- 2015-05-21 IL IL238958A patent/IL238958B/en not_active IP Right Cessation
- 2015-05-22 PH PH12015501150A patent/PH12015501150A1/en unknown
- 2015-05-22 SA SA515360469A patent/SA515360469B1/ar unknown
- 2015-05-22 CL CL2015001392A patent/CL2015001392A1/es unknown
- 2015-06-15 CR CR20150316A patent/CR20150316A/es unknown
- 2015-06-22 EC ECIEPI201526557A patent/ECSP15026557A/es unknown
-
2016
- 2016-03-04 HK HK16102486.9A patent/HK1214593A1/zh not_active IP Right Cessation
-
2017
- 2017-11-24 PH PH12017502141A patent/PH12017502141A1/en unknown
-
2018
- 2018-04-24 JP JP2018082754A patent/JP2018150316A/ja active Pending
- 2018-04-30 AU AU2018202954A patent/AU2018202954A1/en not_active Abandoned
- 2018-08-17 CY CY20181100864T patent/CY1120581T1/el unknown
- 2018-08-21 US US16/107,220 patent/US10689375B2/en active Active
- 2018-10-10 HR HRP20181628TT patent/HRP20181628T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2013011330A (es) | Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso. | |
| JO3148B1 (ar) | مركب مثبط لإشارات مسار notch | |
| MD4684B1 (ro) | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK | |
| IN2014DN10670A (ar) | ||
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| NZ704266A (en) | Inhibitors of alpha-crystallin aggregation for the treatment for cataract | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| PH12015501088A1 (en) | Dimeric compounds | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| PH12015500399A1 (en) | Azaindolines | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug | |
| MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
| TN2013000515A1 (en) | Notch pathway signaling inhibitor compound | |
| UA110834C2 (uk) | Сполука-інгібітор сигнального шляху notch |